VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health

VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health

Gaithersburg, Md.– June 4, 2015 — VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that it has initiated a research collaboration with John’s Hopkins University Bloomberg School of Public Health to research VLP’s malaria vaccine candidates.

“We are very excited with the partnership with the Johns Hopkins University’s Bloomberg School of Public Health. Bloomberg School of Public Health is a leading research institute to conduct science research to treat and control malaria. The School’s extensive experience and expertise in malaria research will facilitate the development of our i-alpha VLP Technology based malaria vaccine candidate” said Dr. Wataru Akahata, Ph.D., Co-Founder and Chief Executive Officer of VLP. “Malaria is one of the most serious public health problems worldwide and a leading cause of death in many developing countries. There were 207 million cases of malaria and 627,000 deaths in 2012, and most of them were children under five years of age. The development of a safe, effective, and affordable malaria vaccine is necessary, however, there is currently no vaccine available. Through our own novel i-alpha VLP Technology, VLP is committed to develop effective vaccine that can eradicate this deadly diseases” Dr. Akahata continued.

About VLP Therapeutics

VLP was established in 2012 by a group of seasoned entrepreneurs based upon a novel, proprietary vaccine technology discovered by its co-founder Dr. Akahata. Its vision is to combat the 21st century global public health problems through revolutionary i-alpha VLP Technology, and the mission is to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, auto-immune diseases and neurological diseases.

About The Johns Hopkins Bloomberg School of Public Health

Since its founding in 1916, the Bloomberg School has advanced research, education and practice to create solutions to public health problems around the world. Faculty, staff and students have helped eradicate smallpox, made water safe to drink, improved child survival, reduced the spread of HIV and uncovered the dangers of tobacco smoke. Researchers and scientists are now discovering ways to eliminate malaria, increase healthy behavior, reduce the toll of chronic disease, improve the health of mothers and infants, and change the biology of aging. Every day, the Bloomberg School works to keep millions around the world safe from illness and injury by pioneering new research, deploying knowledge in the field and educating tomorrow’s public health leaders.

2017-01-11T00:18:18+00:00 2015.06.04|